The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

• Status: Completed
• Trial end date: 2020-01-23
• Target enrollment: 0
• Participant gender: All

Summary

The management of chronic diseases requires a constant monitoring of treatment adherence, in order to obtain an optimal disease control. However, this is often difficult to achieve, especially in pediatric age.

In this sense, for asthmatic patients treated by Symbicort Turbohaler, "AstraZeneca" developed the "Turbo+", an electronic device attached to the Turbohaler, which allows to feel whether the patient does the inhalation, and to register it on a specific application.

The present randomized trial aims to compare the treatment adherence between asthmatic children/adolescents aged 6-17 years treated with Symbicort Turbohaler plus Turbo+ or Symbicort Turbohaler without Turbo+.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy; Istituto per la Ricerca e l'Innovazione Biomedica
• Treatments: Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate

Criteria

Inclusion Criteria:

• uncontrolled mild or moderate persistent asthma;

Exclusion Criteria:

• acute upper respiratory infections;

• immunological or metabolic systemic disease;

• major malformations of the upper airways;

• active smokers.